1. Home
  2. LXEO vs PFD Comparison

LXEO vs PFD Comparison

Compare LXEO & PFD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXEO
    SELLHOLDBUYas of 2 days ago
  • PFD
    SELLHOLDBUYas of 2 days ago
  • Stock Information
  • Founded
  • LXEO 2017
  • PFD 1990
  • Country
  • LXEO United States
  • PFD United States
  • Employees
  • LXEO N/A
  • PFD N/A
  • Industry
  • LXEO
  • PFD Investment Managers
  • Sector
  • LXEO
  • PFD Finance
  • Exchange
  • LXEO Nasdaq
  • PFD Nasdaq
  • Market Cap
  • LXEO 140.6M
  • PFD 144.5M
  • IPO Year
  • LXEO 2023
  • PFD N/A
  • Fundamental
  • Price
  • LXEO $4.10
  • PFD $11.21
  • Analyst Decision
  • LXEO Strong Buy
  • PFD
  • Analyst Count
  • LXEO 5
  • PFD 0
  • Target Price
  • LXEO $22.80
  • PFD N/A
  • AVG Volume (30 Days)
  • LXEO 931.3K
  • PFD 33.2K
  • Earning Date
  • LXEO 03-24-2025
  • PFD 01-01-0001
  • Dividend Yield
  • LXEO N/A
  • PFD 6.30%
  • EPS Growth
  • LXEO N/A
  • PFD N/A
  • EPS
  • LXEO N/A
  • PFD N/A
  • Revenue
  • LXEO N/A
  • PFD N/A
  • Revenue This Year
  • LXEO N/A
  • PFD N/A
  • Revenue Next Year
  • LXEO N/A
  • PFD N/A
  • P/E Ratio
  • LXEO N/A
  • PFD N/A
  • Revenue Growth
  • LXEO N/A
  • PFD N/A
  • 52 Week Low
  • LXEO $2.32
  • PFD $8.53
  • 52 Week High
  • LXEO $19.50
  • PFD $11.18
  • Technical
  • Relative Strength Index (RSI)
  • LXEO 57.61
  • PFD 43.69
  • Support Level
  • LXEO $3.75
  • PFD $11.14
  • Resistance Level
  • LXEO $4.59
  • PFD $11.35
  • Average True Range (ATR)
  • LXEO 0.48
  • PFD 0.10
  • MACD
  • LXEO 0.24
  • PFD -0.00
  • Stochastic Oscillator
  • LXEO 76.89
  • PFD 32.00

Stock Price Comparison Chart: LXEO vs PFD

LXEO
PFD
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober202502468101214161820LXEO VS PFD

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated

Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

Share on Social Networks:

0

By browsing this website, you accept our Privacy Policy & Terms of Use